Data from the ARISER trial indicate that carbonic anhydrase IX (CAIX) score predicts risk of recurrence and survival after curative nephrectomy in patients with localized high-risk clear cell renal carcinoma. Should CAIX staining be quantified to stratify risk after nephrectomy in all such patients?
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Chamie, K. et al. Carbonic anhydrase-IX score is a novel biomarker that predicts recurrence and survival for high-risk, nonmetastatic renal cell carcinoma: data from the phase III ARISER clinical trial. Urol. Oncol. http://dx.doi.org/10.1016/j.urolonc.2015.02.013.
Belldegrun, A. S. et al. ARISER: a randomized double blind phase III study to evaluate adjuvant cG250 treatment versus placebo in patients with high-risk ccRCC: results and implications for adjuvant clinical trials [abstract]. J. Clin. Oncol. 31 (Suppl.), a4507 (2013).
Bui, M. H. et al. Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clin. Cancer Res. 9, 802–811 (2003).
Klatte, T., Kabbinavar, F. F., Zomordian, N., Belldegrun, A. S. & Pantuck, A. J. Prospective evaluation of carbonic anhydrase IX (CAIX) as a molecular marker in metastatic renal cell carcinoma: interim results. J. Urol. 177, 164 (2007).
Shah, R. B., Amin, A., Braun, T. & Redman, B. High carbonic anhydrase (CA) IX protein tissue expression predicts response to interleukin (IL)-2 based therapy for advanced renal cell carcinoma patients. J. Urol. 175, 235 (2006).
Atkins, M., Regan, M., McDermott, D., Mier, J., Stanbridge, E. & Youmans, A. Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer. Clin. Cancer Res. 11, 3714–3721 (2005).
Leibovich, B. C. et al. Carbonic anhydrase IX is not an independent predictor of outcome for patients with clear cell renal cell carcinoma. J. Clin. Oncol. 25, 4757–4764 (2007).
McDermott, D. et al. The high-dose aldesleukin (HD IL-2) “Select” trial in patients with metastatic renal cell carcinoma (mRCC). J. Immunother. 33, 903–904 (2010).
Zang, B. Y. et al. Carbonic anhydrase IX (CAIX) is not an independent predictor of outcome in patients with clear cell renal cell carcinoma (ccRCC) after long-term follow-up. BJU Int. 111, 1046–1053 (2013).
Leibovich, B. C. et al. Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. Cancer 97, 1663–1671 (2003).
Acknowledgements
J.L. is supported by the National Institute for Health Research Royal Marsden Hospital/Institute of Cancer Research Biomedical Research Centre for Cancer.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Pickering, L., Larkin, J. Carbonic anhydrase IX in resected clear cell RCC. Nat Rev Urol 12, 309–310 (2015). https://doi.org/10.1038/nrurol.2015.124
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrurol.2015.124
